Novartis recently announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore. The $256 million investment will facilitate Novartis in deploying digital and automation solutions to enhance manufacturing productivity, improve operational efficiency, and upskill the workforce. The expanded site will focus on manufacturing therapeutic antibody drugs. Source: European Pharmaceutical Manufacturer 18/3/2024